Crux Wealth Advisors Makes New $291,000 Investment in McKesson Co. (NYSE:MCK)

Crux Wealth Advisors bought a new stake in McKesson Co. (NYSE:MCK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 510 shares of the company's stock, valued at approximately $291,000.

A number of other large investors also recently made changes to their positions in MCK. Millstone Evans Group LLC acquired a new position in McKesson in the 4th quarter valued at approximately $28,000. Synergy Asset Management LLC acquired a new position in shares of McKesson in the fourth quarter worth $32,000. Crews Bank & Trust purchased a new stake in shares of McKesson during the fourth quarter worth $33,000. Atala Financial Inc acquired a new stake in McKesson during the fourth quarter valued at $34,000. Finally, Graney & King LLC acquired a new stake in McKesson during the fourth quarter valued at $38,000. Institutional investors and hedge funds own 85.07% of the company's stock.

Insider Activity at McKesson

In related news, CEO Brian S. Tyler sold 8,961 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the sale, the chief executive officer now owns 60,664 shares of the company's stock, valued at $36,276,465.36. The trade was a 12.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Leann B. Smith sold 188 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the sale, the executive vice president now owns 1,051 shares of the company's stock, valued at $640,679.09. This trade represents a 15.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,110 shares of company stock valued at $10,855,706 over the last quarter. 0.11% of the stock is owned by company insiders.

Remove Ads

McKesson Trading Down 0.2 %

MCK traded down $1.55 on Tuesday, hitting $692.43. 670,601 shares of the stock traded hands, compared to its average volume of 883,286. The business has a fifty day moving average price of $646.34 and a two-hundred day moving average price of $595.97. The firm has a market capitalization of $86.78 billion, a PE ratio of 31.70, a P/E/G ratio of 1.29 and a beta of 0.49. McKesson Co. has a 52 week low of $464.42 and a 52 week high of $728.32.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. On average, equities research analysts forecast that McKesson Co. will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 3rd were paid a $0.71 dividend. The ex-dividend date was Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.41%. McKesson's payout ratio is currently 13.00%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MCK shares. Morgan Stanley raised their price target on McKesson from $642.00 to $745.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 2nd. StockNews.com cut shares of McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Cfra Research lowered shares of McKesson from a "moderate buy" rating to a "hold" rating in a research note on Friday, April 4th. Bank of America lifted their price objective on shares of McKesson from $665.00 to $755.00 and gave the company a "buy" rating in a research note on Friday. Finally, Citigroup reduced their price target on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, McKesson has an average rating of "Moderate Buy" and a consensus price target of $668.50.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.